Proleukin. Aldesleukin for Injection



Information for Healthcare Professionals

Read Patient Stories


Facts About Melanoma

More than 53,000 people in the United States are diagnosed with melanoma every year. It is currently the fastest growing cancer, both in the U.S. and worldwide, especially among young adults between the ages of 20 and 30. Melanoma most commonly occurs in women between the ages of 25 and 29 years, and is one of the most common types of cancer in women 30 to 34 years of age, second only to breast cancer. While melanoma is very treatable when caught in the early stages, it is the cause of almost 8,000 deaths annually.

Melanoma risk factors

Individuals are at a higher risk of developing cancer if they have certain characteristics called risk factors. A risk factor is a specific trait or behavior that increases the chance of developing a disease. Melanoma risk factors include the following:

Sensitivity to the sun: Melanoma occurs most often in people with fair, freckled skin who sunburn easily and have red or blond hair with blue eyes. People who have had one or more blistering sunburns before the age of sixteen are also at greater risk. Melanoma is not common in people with dark skin. However, dark skinned people are not immune to melanoma and tend to develop the cancer on the palms of the hands, soles of the feet, in their eyes and under the fingernails and toenails.

Personal and family history: People who have had cancer in the past have a greater risk of developing melanoma. People with a family history of melanoma are also more likely to develop the disease. Ten percent of all melanoma patients have family members who also have had melanoma.

Abnormal moles: A dysplastic nevus can increase the risk of melanoma. These moles can appear anywhere on the body. To learn more about abnormal moles, please read Melanoma Symptoms.*

*For more information on melanoma please refer to the National Cancer Institute and National Institute of Health website at http://www.cancer.gov/cancerinfo/types/melanoma or our Additional Resources and Links Section.



PROLEUKIN Learning Center

PROLEUKIN® Learning Center
Explore the possibilities. To learn more about PROLEUKIN therapy and see if PROLEUKIN therapy is the appropriate treatment for your metastatic melanoma or metastatic kidney cancer, visit the PROLEUKIN Learning Center.

Treatment Center Finder
Treatment Center Regions

“Everyone with metastatic melanoma or metastatic renal cell carcinoma should find out if they are a candidate for PROLEUKIN therapy.”
Dr. Lee Riley, Medical Director, St. Luke’s Cancer Center, Bethlehem, PA.

Click here to find a PROLEUKIN treatment center nearest to your home.

Stay In Touch


> Submit


PROLEUKIN Product Information Line 1-866-9PROLEUKIN
This site intended for U.S. residents only. ©2008 Novartis Pharmaceuticals Corporation.


PROLEUKIN® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma.

Important Safety Information

Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should be used in patients with a normal thallium stress test and a normal pulmonary function test who have a history of cardiac or pulmonary disease.

PROLEUKIN® should be administered in a hospital setting under the supervision of a qualified physician experienced in the use of anticancer agents. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.

PROLEUKIN® administration has been associated with capillary leak syndrome (CLS) which is characterized by a loss of vascular tone, and extravasation of plasma proteins and fluid into the extravascular space. CLS results in hypotension and reduced organ perfusion which may be severe and can result in death. CLS may be associated with cardiac arrhythmias (supraventricular and ventricular), angina, myocardial infarction, respiratory insufficiency requiring intubation, gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental status changes.

PROLEUKIN® treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of PROLEUKIN® therapy. Patients with indwelling central lines are particularly at risk for infection with gram positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin, or vancomycin has been associated with a reduced incidence of staphylococcal infections.

PROLEUKIN® administration should be withheld in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.

Please see complete prescribing information, including box warning.

The content contained in this website is not intended to be a substitute for professional medical advice related to any topic discussed. Patients are urged to consult with their treating physicians or other professionals. Never disregard professional,medical or legal advice or delay seeking such advice because of something you have read on this website.


PROLEUKIN.com Home  |  What is PROLEUKIN & how does it work?  |  Metastatic Melanoma
Metastatic Kidney Cancer  |  PROLEUKIN Treatment Centers
Additional Resources and Links  |  Stay in Touch  |  Prescribing Information
Important Safety Information  |  INFORMATION FOR HEALTHCARE PROFESSIONALS

Contact Us  |  Site Guide  |  Site Map
Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement.
Copyright ©2008 Novartis Pharmaceuticals Corporation. All rights reserved.